159 related articles for article (PubMed ID: 25322686)
1. Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.
Pardanani A; Abdelrahman RA; Finke C; Lasho TT; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Tefferi A
Leukemia; 2015 Mar; 29(3):741-4. PubMed ID: 25322686
[No Abstract] [Full Text] [Related]
2. Calr type 1/like mutation in myelofibrosis is the most prominent predictor of momelotinib drug survival and longevity without transplant.
Tefferi A; Pardanani A; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Ketterling RP; Reichard KK; Gangat N
Blood Cancer J; 2024 Mar; 14(1):51. PubMed ID: 38503764
[No Abstract] [Full Text] [Related]
3. ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis.
Guo Y; Zhou Y; Yamatomo S; Yang H; Zhang P; Chen S; Nimer SD; Zhao ZJ; Xu M; Bai J; Yang FC
Leukemia; 2019 May; 33(5):1287-1291. PubMed ID: 30651633
[No Abstract] [Full Text] [Related]
4. Momelotinib for myelofibrosis: our 14 years of experience with 100 clinical trial patients and recent FDA approval.
Tefferi A; Pardanani A
Blood Cancer J; 2024 Mar; 14(1):47. PubMed ID: 38499521
[No Abstract] [Full Text] [Related]
5. Myelofibrosis with a novel translocation, t(1;3)(q31;q23), and response to imatinib mesylate.
Yalamanchili K; Liu D; Seiter K
Leukemia; 2007 Mar; 21(3):577-8. PubMed ID: 17230224
[No Abstract] [Full Text] [Related]
6. Momelotinib therapy for myelofibrosis: a 7-year follow-up.
Tefferi A; Barraco D; Lasho TL; Shah S; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Gangat N; Pardanani A
Blood Cancer J; 2018 Mar; 8(3):29. PubMed ID: 29515114
[TBL] [Abstract][Full Text] [Related]
7. Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Hudgens S; Verstovsek S; Floden L; Harrison CN; Palmer J; Gupta V; McLornan D; McMullin MF; Kiladjian JJ; Foltz L; Platzbecker U; Fox ML; Mead AJ; Ross DM; Oh ST; Perkins AA; Leahy MF; Deheshi S; Donahue R; Klencke BJ; Mesa RA
Value Health; 2024 May; 27(5):607-613. PubMed ID: 38311180
[TBL] [Abstract][Full Text] [Related]
8. AEL transformed from post-ET myelofibrosis with a sinusoidal pattern, JAK2 mutation, and biallelic TP53 inactivation.
Wei Q; You MJ
Blood; 2024 May; 143(20):2107. PubMed ID: 38753354
[No Abstract] [Full Text] [Related]
9. Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.
Harrison C; Yacoub A; Scott B; Mead A; Gerds AT; Kiladjian JJ; Mesa R; Egyed M; Scheid C; Gutierrez VG; O'Sullivan J; Buckley S; Kanellopoulos K; Mascarenhas J
Haematologica; 2023 Jul; 108(7):1960-1964. PubMed ID: 36601980
[No Abstract] [Full Text] [Related]
10. Normal karyotype in myelofibrosis: is prognostic integrity affected by the number of metaphases analyzed?
Nicolosi M; Mudireddy M; Gangat N; Pardanani A; Hanson CA; Ketterling RP; Tefferi A
Blood Cancer J; 2018 Jan; 8(1):8. PubMed ID: 29330482
[No Abstract] [Full Text] [Related]
11. [Momelotinib bei Myelofibrose und Anämie].
Acta Haematol; 2024; 147(2):251-253. PubMed ID: 38467116
[No Abstract] [Full Text] [Related]
12. Hidden conformational codes.
Lv K; Tong W
Blood; 2023 Nov; 142(21):1766-1768. PubMed ID: 37995103
[No Abstract] [Full Text] [Related]
13. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis.
Abdelrahman RA; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Pardanani A; Tefferi A
Br J Haematol; 2015 Apr; 169(1):77-80. PubMed ID: 25511866
[TBL] [Abstract][Full Text] [Related]
14. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Blood; 2014 Dec; 124(24):3529-37. PubMed ID: 25472969
[TBL] [Abstract][Full Text] [Related]
15. Molecular diagnostics of myeloproliferative neoplasms.
Langabeer SE; Andrikovics H; Asp J; Bellosillo B; Carillo S; Haslam K; Kjaer L; Lippert E; Mansier O; Oppliger Leibundgut E; Percy MJ; Porret N; Palmqvist L; Schwarz J; McMullin MF; Schnittger S; Pallisgaard N; Hermouet S;
Eur J Haematol; 2015 Oct; 95(4):270-9. PubMed ID: 25951317
[TBL] [Abstract][Full Text] [Related]
16. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
Al Assaf C; Van Obbergh F; Billiet J; Lierman E; Devos T; Graux C; Hervent AS; Emmerechts J; Tousseyn T; De Paepe P; Papadopoulos P; Michaux L; Vandenberghe P
Haematologica; 2015 Jul; 100(7):893-7. PubMed ID: 25934766
[TBL] [Abstract][Full Text] [Related]
17. Therapy for myeloproliferative neoplasms: when, which agent, and how?
Geyer HL; Mesa RA
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):277-86. PubMed ID: 25696867
[TBL] [Abstract][Full Text] [Related]
18. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
Mesa RA; Passamonti F
Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
[TBL] [Abstract][Full Text] [Related]
19. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
Komrokji RS; Seymour JF; Roberts AW; Wadleigh M; To LB; Scherber R; Turba E; Dorr A; Zhu J; Wang L; Granston T; Campbell MS; Mesa RA
Blood; 2015 Apr; 125(17):2649-55. PubMed ID: 25762180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
